A new Montana law limits how insurers can delay coverage of cancer medications—and it affects how you manage your health plan.
Most Montana health services owners don't realize that a provision buried in SB422, passed during the 2025 legislative session, has quietly changed the rules for how group health insurance plans can cover advanced cancer drugs. If your organization sponsors a health plan for employees, this matters.
SB422 prohibits insurers from requiring step therapy—also called fail-first requirements—before covering FDA-approved cancer drugs that align with National Comprehensive Cancer Network (NCCN) guidelines. Step therapy is a cost-control tool that typically requires patients to try cheaper or less intensive treatments first and fail before insurance will pay for a more advanced drug.
For advanced or metastatic cancer patients, this requirement can mean weeks or months of delay while trying drugs that may not work for their specific condition. The new law removes that barrier for treatments that meet NCCN standards, which are evidence-based clinical guidelines developed by leading cancer centers.
If you sponsor a group health insurance plan—whether you're a hospital system, clinic network, or any employer offering coverage—your plan documents and insurer agreements may now be out of compliance. This applies to any plan that covers employees with advanced cancer diagnoses.
The restriction applies specifically to drugs that are both FDA-approved and consistent with NCCN guidelines. Plans cannot impose step-therapy barriers to these medications.
Review your current health plan documents and your insurer's formulary and prior-authorization policies. If your plan or insurer currently requires step therapy for any cancer drugs meeting the law's criteria, you'll need to amend those policies.
This likely means:
• Requesting policy updates from your health plan carrier or third-party administrator
• Reviewing your plan documents for step-therapy language related to cancer drugs
• Understanding that removing step-therapy requirements may increase plan costs, since patients will have faster access to higher-cost medications
• Planning budget adjustments if you self-insure or have significant cost-sharing arrangements
SB422 was enrolled during the 2025 legislative session. The provision appears in Section 1, Page 1 of the bill. No explicit effective date is stated in the law, which typically means it becomes effective on the date of enactment. You should treat this as a current compliance requirement and contact your insurer or plan administrator immediately to confirm your plan's status.
Because cancer treatment decisions often happen quickly, and because patients may already be experiencing delays under current step-therapy rules, treating this as urgent is prudent.
The balance between cost management and patient access is real, and this law reflects a policy choice to prioritize rapid access to evidence-based advanced cancer treatments. Health plan sponsors should understand both the clinical rationale and the financial implications as they implement compliance.
For a detailed, business-specific guide to SB422 compliance tailored to your plan type, contact your health plan carrier or a benefits consultant familiar with Montana law.